Status:
TERMINATED
Renal Mechanism of Action/Splay vs. TmG
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Diabetes, NOS
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the effects of dapagliflozin to promote glucose loss in urine in healthy subjects and subjects with type 2 diabetes mellitus
Eligibility Criteria
Inclusion
- Male and female subjects
- Age 18 to 65 years
- BMI 18 to 35 kg/m2
- Healthy subjects and subjects with type 2 diabetes mellitus on 1 of the following therapies: diet, sulfonylurea, and/or metformin
- No evidence of impaired renal function
Exclusion
- Unwilling or unable to use an acceptable method of birth control
- Subjects with type 1 diabetes mellitus, heart disease, hepatic C or B
- Exposure to insulin
- Use of exclusionary concomitant medications
- Evidence of significant kidney disease or any other significant medical or psychiatric disorder
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00726505
Start Date
June 1 2009
End Date
August 1 2009
Last Update
October 17 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Of Texas Health Center At San Antonio
San Antonio, Texas, United States, 78229